Pharmacology

Action Mechanism of Action Reference
INHIBITOR Sclerostin inhibitor

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Osteoporosis, Postmenopausal 4 D015663 ClinicalTrials
Osteogenesis Imperfecta 3 D010013 ClinicalTrials
Fractures, Bone 2 D050723 ClinicalTrials
Bone Diseases, Metabolic 1 D001851 ClinicalTrials

Cross References

Resources Reference
CAS NUMBER 909395-70-6
ChEMBL CHEMBL2107874
FDA SRS 3VHF2ZD92J
Guide to Pharmacology 8092